Moximed, Inc.
Moximed, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Moximed, Inc..
Moximed, Inc. is a company.
Key people at Moximed, Inc..
Key people at Moximed, Inc..
Moximed, Inc. is a medical device company focused on improving care for patients with knee osteoarthritis (OA). Its flagship product, the MISHA Knee System, is an implantable shock absorber designed to unload the knee joint, relieve pain, and improve function for patients who have not found relief from other treatments and are not yet candidates for knee replacement surgery. Moximed serves orthopedic surgeons and patients suffering from medial compartment knee OA, addressing a significant unmet clinical need with a minimally invasive solution that offers quick recovery. The company has demonstrated strong growth momentum, recently closing a $91 million Series D financing round to accelerate commercialization and expand patient and surgeon access to its technology[1][2][5].
Founded in 2006 by Josh Makower, Moximed emerged from the recognition that load management in knee OA could be effectively addressed with an implantable shock absorber. The idea was born from over a decade of clinical research and development, with early traction gained through persistent refinement and validation of the MISHA Knee System’s clinical value. The company introduced its first implantable shock absorber platform in 2014, and pivotal clinical study data have since validated the product’s ability to reduce pain and improve function in patients with medial knee OA. Leadership has evolved with Christopher Gleason appointed CEO in 2024 to lead the company through its next growth phase[1][2][4].
Moximed rides the growing trend toward less invasive, joint-preserving treatments for osteoarthritis, a condition affecting millions worldwide with limited effective options short of joint replacement. The timing is favorable due to increasing demand for outpatient orthopedic solutions that improve quality of life while delaying or avoiding surgery. Market forces such as an aging population, rising OA prevalence, and healthcare cost pressures support adoption of innovative devices like MISHA. Moximed’s technology influences the broader ecosystem by expanding treatment paradigms and offering surgeons new tools to manage OA earlier and more effectively[2][5].
Moximed is positioned for significant growth as it scales commercialization of the MISHA Knee System and expands surgeon and patient access. Future trends shaping its journey include advances in implantable device technology, increasing emphasis on personalized and minimally invasive orthopedic care, and growing awareness of alternatives to joint replacement. The company’s influence is likely to evolve as it demonstrates long-term clinical benefits and potentially expands its platform to other joints or indications. Moximed’s pioneering approach could redefine standards of care for knee OA, offering a new beginning for millions of patients suffering from this chronic condition[2][4][5].
